Key statistics
As of last trade, Eupraxia Pharmaceuticals Inc (EPRX:NAQ) traded at 2.78, 26.36% above the 52 week low of 2.20 set on Oct 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.85 |
---|---|
High | 2.85 |
Low | 2.78 |
Bid | 2.78 |
Offer | 2.91 |
Previous close | 2.90 |
Average volume | 38.54k |
---|---|
Shares outstanding | 35.62m |
Free float | 30.47m |
P/E (TTM) | -- |
Market cap | 142.49m CAD |
EPS (TTM) | -1.37 CAD |
Data delayed at least 15 minutes, as of Nov 13 2024 15:31 GMT.
More ▼
Press releases
- Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
- Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
- Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
- Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
- Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
- Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
- Eupraxia Pharmaceuticals Strengthens Senior Management Team
- Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases
- Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
- Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
More ▼